Elite Pharmaceuticals Reports Positive Results from Pivotal Bioequivalence Study
Northvale, NJ – June 15, 2026 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company focused on the development, manufacture, and distribution of niche generic products, has announced the successful completion of a pivotal bioequivalence study for an undisclosed generic anticonvulsant drug product.
Key Highlights for Investors
- Positive Pivotal Study Results: The recently completed bioequivalence study demonstrated that Elite’s generic product is bioequivalent to the branded reference product. The study was designed as an open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence crossover trial in normal, healthy adult subjects under fasting conditions.
- Significant Market Opportunity: According to IQVIA, the combined branded and generic sales for this anticonvulsant product were reported at \$840 million for the twelve months ending April 2026. This highlights a substantial addressable market if Elite’s product is approved and launched.
- Regulatory Progress: Elite is in the process of compiling the study data to file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA). Approval of this application would allow the company to market its generic version in the United States.
Potential Impact on Shareholders
- Price-Sensitive Information: The positive outcome of this pivotal study, and the imminent ANDA filing with the FDA, represent significant milestones. Success at the FDA could enable Elite to capture market share in a high-value segment, which could materially impact future revenues and potentially drive share price appreciation.
- Product Portfolio and Manufacturing Capabilities: Elite’s business model focuses on niche generics, with product lines that include immediate-release and controlled-release solid oral dose products. These are marketed both under the Elite Laboratories label and through third-party partners. The company operates a cGMP and DEA-registered facility in Northvale, NJ, supporting its internal R&D and manufacturing.
Forward-Looking Statements & Risks
Elite Pharmaceuticals has cautioned investors that forward-looking statements—including expectations regarding FDA approval and future performance—are subject to risks, uncertainties, and factors beyond the company’s control. These statements are not guarantees of future results, and actual outcomes may differ materially. Investors are advised to review Elite’s filings with the Securities and Exchange Commission (SEC) for a comprehensive discussion of risks.
Contact Information
For further details, investors can contact:
Dianne Will, Investor Relations
Tel: 518-398-6222
Email: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review all publicly available information and consult their financial advisor before making investment decisions.
